due to scientific misconduct.
14 Nonetheless, the interpretation of some of the negative reports has raised a number of issues such as the insufficient number of patients and shortness of follow-up preventing detection of significant differences between the compared treatments, as well as the inadequacy of some of the control arms. 15 In addition, HDC has proved its value in other neoplastic diseases such as lymphomas, 16, 17 multiple myeloma 18 and possibly germ cell tumors, [19] [20] [21] whenever the procedure and the indications have been adequately established. Therefore, while the currently available data does not recommend the use of HDC in common clinical practice, the validation in the context of controlled clinical trials of alternative approaches that may improve its results is clearly warranted. 15, 22 Different methods have been suggested in order to improve the efficacy of currently employed HDC regimens, such as using drugs other than just alkylating agents, avoiding the risk of reinfusion of grafts contaminated by cancer cells or delivering more than a single cycle of HDC. We planned a phase I trial to develop a HDC scheme applying this rationale. This regimen was designed to be less toxic than conventional intensive regimens and to be managed mainly in an outpatient setting. Such a regimen could gather the potential advantages of HDC while being safer, more affordable and avoiding the potential risks of tumor cell reinfusion.
For the design of our trial, we employed a combination of mitoxantrone (MTZ) and cyclophosphamide (CTX), drugs which have shown activity at standard doses, as single agents or in combination, in the treatment of several hematological and solid tumors, including breast cancer. 23, 24 MTZ is a synthetic anthracenedione that does not produce the quinone-type free radicals that probably mediate the anthracycline-related cardiac toxicity and is therefore associated with less cardiotoxicity. Myelosuppression constitutes its dose-limiting toxicity. In vitro, MTZ had a steeper dose-response effect in breast cancer models than doxorubicin, 2 which makes it a good candidate for HDC. 25 When given along with colony-stimulating factors (CSF), MTZ can be safely delivered in sequential cycles at doses ranging from 28 to 32 mg/m 2 . 26, 27 CTX is an alkylating agent widely used in many HDC combinations. When administered with CSF, CTX can be delivered at doses up to 7 g/m 2 without hematopoietic support.
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Patients and methods

Patient selection
Patients were included from the following diagnostic groups: metastatic cancer in complete or partial response after standard chemotherapy, or with no evidence of disease after surgery or radiotherapy (stage IV NED), and high-risk breast cancer (five or more positive axillary nodes) after conventional adjuvant treatment. Additional inclusion criteria were: age 18 to 60 years, ECOG performance status 0 or 1, life expectancy greater than 12 weeks, absence of previous cardiovascular disease or other poorly controlled medical illness, adequate cardiac, renal, hepatic and hematological function (left ventricular ejection fraction (LVEF) у50% measured by resting multigated nuclear scans (MUGA), creatinine Ͻ1.2 mg/dl; total bilirubin Ͻ1.5 mg/dl; absolute neutrophil count (ANC) Ͼ1.5 ϫ 10 9 /l; and platelets Ͼ100 ϫ 10 9 /l), informed consent prior to initiating therapy and adequate access to hospital (within 1 h). Exclusion criteria were: confirmed central nervous system metastases or carcinomatous lymphangitis; treatment with chemotherapy or radiotherapy within 3 weeks prior to study entry; more than one previous regimen of prior chemotherapy (including adjuvant or neoadjuvant therapy); treatment with more than 350 mg/m 2 of doxorubicin or 525 mg/m 2 of 4-epirubicin; and previous treatment with radiotherapy through a left chest port. The protocol was reviewed by an Ethics Committee.
Pre-treatment evaluation
Before treatment, all patients were evaluated with medical history, physical examination, blood counts and chemistry, and LVEF measured by MUGA. In high-risk breast cancer patients, distant disease was excluded by chest radiograph, bone scan and abdominal ultrasound or computerized tomography (CT). Ovarian cancer patiens were evaluated with abdominal CT and chest radiograph or CT. Tumor markers were determined when appropriate. Other tests were performed when required according to clinical and/or complementary examination data. MUGA was repeated after completing treatment. . Two consecutive cycles were administered with a 4 week interval. In order to receive the second cycle, patients should have recovered from any non-hematological grade III and IV toxicities, ANC should be above 1.5 ϫ 10 9 /l, platelets over 100 ϫ 10 9 /l and performance status had to be 0 or 1. If patients had not recovered from the first cycle, 2 additional weeks were allowed for observation. Patients not recovered after that period were not to receive the second cycle.
Treatment plan
Patients were admitted to the hospital for chemotherapy administration for 36 to 48 h. Pre-hydration consisted of 3000 cm 3 of dextrose-saline given over 12 h before treatment. CTX was administered diluted in 2000 cm 3 of 5% dextrose over 90 min. MTZ was then given diluted in 250 cm 3 5% dextrose over 15 min. Post hydration consisted of 4000 cm 3 of dextrose-saline given over 24 h. Mesna was administered before CTX (2 g/m 2 i.v.) and with the post hydration (3 g/m 2 i.v.). Antiemetic therapy with ondasetron and dexamethasone was provided, as well as furosemide after CTX to ensure proper diuresis.
After chemotherapy, patients were discharged and they were followed on an outpatient basis. They all received subcutaneous granulocyte colony-stimulating factor (G-CSF) 300 g/24 h and antimicrobial prophylaxis with oral ciprofloxacin 500 mg/12 h from the day of discharge until ANC was above 0.5 ϫ 10 9 /l. Once the two cycles had been completed, hormonal or radiation therapy was administered when indicated according to standard criteria. No more chemotherapy treatment was allowed until progression.
Follow-up and toxicity assesment
Patients were seen every 2 to 4 days in an outpatient setting, starting on the 6th day after discharge. Blood counts were performed on each visit. Platelet transfusions were administered if platelets were below 20 ϫ 10 9 /l and packed red cells (PRC) were transfused according to common clinical criteria. Transfusions were performed at the day hospital. Patients developing febrile neutropenia were admitted to the hospital and received standard treatment while maintaining G-CSF. Toxicity was graded according to the World Health Organization (WHO) scale.
Definition of dose-limiting toxicity, maximum tolerated dose and criteria for dose escalation
Dose escalation was based on the number of patients who experienced dose-limiting toxicity (DLT) during each cycle. DLT was defined as ANC below 0.5 ϫ 10 9 /l lasting more than 7 days, platelets below 20 ϫ 10 9 /l requiring more than one platelet transfusion or grades 3-4 non-hematological toxicity (excluding alopecia). Four patients were to be treated with two cycles at each level. Escalation to the next level proceeded if DLT was present in less than half of the cycles given at the previous level. If DLT occurred in one patient, three or four more patients were included at the same level. Maximum tolerated dose (MTD) was defined as the highest dose level at which less than 50% of the cycles developed DLT. No intrapatient escalation or dose reductions were allowed.
Results
Patient characteristics
Thirty-one patients were treated between September 1994 and June 1996. Median age was 44 years (range 18-64). Sixteen had high-risk breast cancer; 10 had metastatic breast cancer (MBC); four had advanced ovarian cancer; and one had metastatic Ewing sarcoma. Additional characteristics are described in Table 1 .
Treatment administration
All patients received the planned treatment. The median interval between the two cycles was 32 days (range 21-55). Follow-up after each cycle was carried out in an outpatient setting, and only patients developing febrile neutropenia required additional hospital admission. There were no toxic deaths.
Results of dose escalation
Escalation proceeded up to the fourth level in which we found an unacceptable toxicity according to the established criteria. Therefore, we chose the third level (MTZ 25 mg/m 2 and CTX 4000 mg/m 2 ) as the MTD. The main DLT was hematological, especially ANC below 0.5 ϫ 10 9 /l lasting more than 7 days and platelets below 20 ϫ 10 9 /l requiring more than one platelet transfusion. Non-hematological DLT included grade III emesis, asthenia and mucositis. More information is displayed in Table 2 . 
Hematological toxicity
Grade IV neutropenia (ANC Ͻ0.5 ϫ 10 9 /l) was universal with a median duration of 6 days. Neutropenia below 100/mm 3 developed in 54 cycles (87%) and lasted a median period of 4 days when it was present. Platelet count dropped below 20 ϫ 10 9 /l in 30 cycles (48%), with a median recovery period of 4 days. Blood counts were performed 2 to 3 months after completing therapy. Twentynine out of 30 patients showed WBC above 2.5 ϫ 10 9 /l and 25 ANC of 1.5 ϫ 10 9 /l or greater. Platelets were over 100 ϫ 10 9 /l in all patients. Hematological toxicity is described in Table 3 .
Platelet transfusions were required in 29 cycles (47%) and PRC were administered in 15 cycles (24%). Globally, some kind of transfusional therapy was performed in 21 patients (68%): 19 (61%) received platelet transfusions, 12 (39%) received PRC, and 10 patients (32%) required both kinds of blood products. G-CSF was administered for a median period of 13 days (range 10-16). More information is displayed in Table 4 .
Febrile neutropenia occurred in 18 cycles (29%). Surprisingly, the greatest incidence occurred at the first level which harbored half of the total number of episodes. Distribution of febrile neutropenia by levels was: level 1: nine episodes; level 2: one episode; level 3: five episodes; and level 4: three episodes. One patient, treated at the third level, developed a bacterial pneumonia shortly after receiving the second cycle. She underwent a long-term grade IV neutropenia lasting 16 days and prolonged thrombopenia, requiring several platelet transfusions. She also had a mild renal failure with severe hypokalemia, probably due to nephrotoxic drugs. She finally recovered completely without requiring intensive care unit admission. In the rest of the patients, febrile neutropenia was uncomplicated.
Non-hematological toxicity
Ten patients (16%) had grade III emesis. Overall, some grade of emesis was present in 41 of the 61 cycles administered (66%). Grade III mucositis happened in six cycles (10%) and grade I or II mucositis in 11 cycles (18%). Mild fatigue was frequently reported although there were only five cases (9%) of grade III asthenia. No grade IV nonhematological toxicities were observed. Less frequent adverse effects that could be attributed to chemotherapy were: diarrhea (one patient grade III and one grade II); grade II hyperbilirubinemia (one episode) and hand-foot syndrome (one episode).
There was no acute cardiac toxicity. LVEF data are available from 27 patients before and after treatment. Twentyfive patients had both measurements done. Median LVEF was 60% before treatment (range 50-67%) and median decrease of LVEF was 2.4%. There were two patients with a 12% decrease in LVEF, two with 9% and one with 8%.
Long-term toxicity
One patient, treated at the first level, developed congestive heart failure 2 years after treatment. She had received 450 mg/m 2 of 4-epirubicin before high-dose therapy and she a Only includes data from cycles in which patients experienced this toxicity (n = number of cycles).
had a 50% LVEF before treatment. Although her LVEF remained stable immediately after chemotherapy (51%) her latest measures ranged from 34 to 43%. We collected data on LVEF from 14 patients carried out 1 year or later after treatment. Only three were below 50% (including the patient mentioned above and one who later received HDC with hematopoietic support). Two of the patients who developed the greatest decreases in LVEF after treatment (8% and 12%), showed normal results.
One patient was diagnosed with myelodysplastic syndrome 33 months after treatment. She was treated at the first level and developed a refractory anemia with excess of blasts with translocation (1:3) and deletion of 6p and 13q. The diagnosis was pursued after the development of moderate neutropenia and thrombopenia. She received a bone marrow transplant from her matched brother and is currently asymptomatic. There were no other long-term toxicities found, despite a minimum follow-up of 3 years for all the patients except one.
Discussion
The use of HDC for solid tumors, especially breast cancer, has been a matter of interest during the past years. The results of the prospective trials released to date, have nonetheless prompted the necessity of exploring variations in the current design of HDC combinations, and several suggestions have been raised to increase their efficacy. The first is to select more adequately the drugs used, 15 since this selection is too often based upon toxicity profiles rather than on anti-tumoral activity. Indeed, many of the commonly used HDC schemes employ drugs that are not among the most active ones at standard doses for the treatment of breast cancer, such as cisplatin, carboplatin, BCNU or melphalan. [6] [7] [8] [9] [10] [11] In the second place, the possibility of disease relapse due to reinfusion of hematological products contaminated by neoplastic cells is another point of concern. It is known that tumor cells may contaminate bone marrow harvests as well as blood stem cell collections from breast cancer patients, although the clinical relevance of this fact is conflicting: some authors have not found an increased risk of relapse when there is tumor contamination of grafts, 29 while others have, at least for some patient subsets. 30, 31 Nonetheless, tumor contamination of reinfused hematopoietic products has been correlated with disease relapse in hematological as well as in solid tumors 32, 33 and may also have a role in breast cancer. The strategies to avoid this potential contamination are either to purge the reinfusion products or, as we did, to eliminate the use of hematological cell support. Finally, some authors have hypothesized that a single cycle of HDC may be unable to eradicate all cancer cells, 34, 35 based on tumor cell growth considerations, and tandem cycles of HDC have been proposed.
We have developed a regimen using high doses of MTZ and CTX that can be safely delivered in two consecutive 121 Table 4 Hematological support . These doses are higher than those previously reported using the same drugs with G-CSF support, [36] [37] [38] and in fact they are very similar to the doses used in conventional HDC with hematopoietic cell support. Our regimen took place mainly in an outpatient setting, representing a remarkable advantage over the majority of the HDC programs. Patients were seen every 2 to 4 days and this provided a convenient control of both hematologic and non-hematologic toxicities. There were no episodes of bleeding related to thrombopenia and, when required, blood and platetelet transfusions were performed at the day hospital.
Other investigators have reported HDC regimens that do not use hematological cell support, although the toxicity was substantially higher than in our combination. Herzig et al 39 employed high doses of CTX and etoposide, but toxicity was severe, with prolonged hematologic recovery periods and a 6% treatment-related mortality rate, indicating that the use of stem cell support could be warranted. Morgan et al 40 delivered two cycles of high-dose CTX along with doxorubicin escalation, achieving a recommended phase II dose of 150 mg/m 2 . Febrile neutropenia rates were around 70%, and all patients required long-term admissions (median 23 days) and aggressive supportive care, including total parenteral nutrition in many cases. This indicates that, although doxorubicin is one the most active single agents for breast cancer, its toxicity profile precludes it from being a good candidate for HDC. Finally, in a phase II trial reported by Neidhart et al, 41 51 patients with refractory malignancies were treated with high doses of CTX, etoposide and cisplatin with CSF support, and there were six non-disease-related deaths within 30 days after completing treatment.
Some randomized trials have tested combinations including high-dose MTZ for breast cancer treatment. Namer et al 37 compared conventional therapy with CTX and doxorubicin vs MTZ 23 mg/m 2 and CTX 600 mg/m 2 in high-risk breast cancer patients (у10 involved nodes), with G-CSF Bone Marrow Transplantation support. Seventy-four patients received the standard-dose treatment and 76 were randomized to the high-dose arm. After a median follow-up of 5 years there was a significant disease-free survival improvement for the HDC arm (19% vs 49%, P = 0.02) and a trend towards improved overall survival (OS) (40% vs 52%, P = 0.13) in very high-risk patients (у15 axillary nodes involved). Lotz et al 10 randomized patients with MBC after four to six courses of conventional anthracycline-based chemotherapy to either continue the same therapy or to receive high doses of MTZ (45 mg/m 2 ), CTX (120 mg/kg) and melphalan (140 mg/m 2 ) with G-CSF and stem cell support. Twenty-nine patients received conventional treatment and 32 intensive therapy. The relapse rates at 2 years were lower for HDC (52% vs 27%) and median progression-free survival was also improved (15.7 vs 26.9 months, P = 0.04). Even though OS was not statistically different, there was a trend favoring the intensive group (15.7 vs 36.1 months, P = 0.08). In an update of the results, relapse rates at 3 years still favored the intensive group (50.8% vs 79.3%) and, although relapse rates at 5 years were nearly identical (90.8% vs 90.7%), the OS rate at that time still showed a similar trend favoring HDC (18.5% vs 29.8%). 42 Based on these results, it seems that intensification regimens containing high-dose MTZ and CTX might be more active than those including just alkylating agents or drugs which are not very active at conventional doses.
Long-term toxicity is frequently not reported in HDC trials. In our study, after a minimum follow-up of 3 years we observed one episode of cardiac failure and one case of myelodysplasia. MTZ may cause decreases in the LVEF, especially in patients treated with prior anthracyclines. The patient developing cardiac failure had received 450 mg/m 2 of 4-epirubicin. This suggests that the level of prior anthracycline exposure should be limited before treatment with high-dose MTZ. Myelodysplasia and other clonal hematological diseases such as acute leukemias have been described following intensified chemotherapy for breast cancer. Although the reported 4-year probability in large series has been less than 2%, 43, 44 oncologists must be concerned with the possibility of this complication when evaluating the real efficacy of HDC and in the follow-up of these patients.
In summary, we have been able to deliver two cycles of high doses of MTZ and CTX with G-CSF after conventional chemotherapy, without requiring hematopoietic cell support. Acute toxicity was predictable and non-lifethreatening, and treatment took place mainly in an outpatient setting. This regimen avoids some potential drawbacks of HDC regimens currently employed. The combination is being further explored in a phase II trial directed to obtain more data on toxicity as well as on efficacy.
